Remove privacy-policy
article thumbnail

ACI To Host Multiple Events Featuring HP&M Speakers – Discounts Available to FDA Law Blog Readers

FDA Law Blog: Biosimilars

John counsels FDA-regulated entities on litigation, enforcement, and compliance matters including FDA inspections, Form 483s, Warning and Untitled Letters and Consent Decrees, internal investigations, and data privacy concerns. More information about the conference can be found here. FDA Law Blog readers can use discount code S10-866-866L24.S

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

Companies may communicate with HCPs, HCOs, and POs using these channels, but must take care to comply with legislation regarding data privacy and electronic communications, and must allow persons the option to opt-out of receiving such communications. About the authors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

To keep the EU’s medicine supply intact, Gupta suggests governments should adopt new pricing policies and provide further aid to mitigate the impact of rising operational costs; they should also minimise the exodus of generics manufacturers.

article thumbnail

WHO cough mixture health alerts raises questions about slack compliance in manufacturing

Pharmaceutical Technology

In this instance of contaminated cough syrups, the concern is around an excipient in the product and not the active pharmaceutical ingredient (API). It is therefore essential that all components used in the pharmaceutical manufacturing process and not just the API must be assessed and tested to full monograph specifications.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

To build an advanced pharmaceutical manufacturing cluster in the Richmond-Petersburg area, the Alliance for Building Better Medicine aims to support the early growth of local pharmaceutical manufacturers. The US Department of Commerce’s Economic Development Administration (EDA) awarded the organization $52.9

article thumbnail

Higher throughput integrity testing: Defining a modern CCIT system for the demands of serial production

Pharmaceutical Technology

Container Closure Integrity Testing (CCIT) is used to evaluate the ability of a pharmaceutical’s primary packaging to protect the sterility of its contents. On a regular basis, pharmaceutical manufacturers are performing CCIT during commercial production to ensure that packaging processes are operating as they should.

article thumbnail

The rising importance of containment in small molecule drug development

Pharmaceutical Technology

Despite the current emphasis on biologic medicines, small molecule drugs still dominate the pharmaceutical manufacturing world. Within the small molecule landscape, several trends are shaping the industry’s future, one of the most notable being the rise of high-potency active pharmaceutical ingredients (HPAPIs).